Brainstorm Cell Therapeutics In (BCLI) Financials

BCLI Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 5.7 million 8.3 million
2023-06-30 5.7 million 9.6 million
2023-03-31 7.9 million 12.7 million
2022-12-31 8.5 million 11.5 million

BCLI Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -6.4 million 548000
2023-06-30 -6.8 million 988000
2023-03-31 -4.0 million 4000
2022-12-31 -4.6 million 377000

BCLI Net Income

No data available :(

BCLI Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 1.4 million - 2.9 million
2023-06-30 748000 - 3.3 million
2023-03-31 2.2 million - 3.7 million
2022-12-31 3.0 million - 4.1 million

BCLI Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 44.3 million
2023-06-30 39.7 million
2023-03-31 36.7 million
2022-12-31 36.5 million

BCLI Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 18000 3.3 million 2.7 million -
2023-06-30 - 2.8 million 2.7 million -
2023-03-31 - 2.9 million 2.2 million -
2022-12-31 29000 2.5 million 2.5 million -

BCLI Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 - 65000
2023-06-30 154000 67000
2023-03-31 -497000 497000
2022-12-31 - 70000

BCLI

Price: $0.38

52 week price:
0.13
3.37

Earnings Per Share: -0.42 USD

P/E Ratio: -0.92

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 566900

Ebitda: -2.4 million

Market Capitalization: 28.3 million

Links: